1. Meaning of Sponsor Indemnification

Sponsor indemnification is a contractual undertaking by the clinical-trial sponsor—usually a pharmaceutical/biotech company—to protect the investigator, hospital/institution and sometimes their personnel from specified claims, losses, damages, costs and liabilities arising from the clinical trial.

A typical clause may provide that:

The Sponsor shall indemnify and hold harmless the Institution and Investigator against third-party claims arising from injury caused by the investigational product or trial procedures, subject to specified exclusions.

The critical issue is:

Does the sponsor's indemnity cover medical malpractice/negligence committed by the investigator or hospital?

Usually, the answer is not automatically. The scope depends on:

1. the wording of the indemnity clause;
2. the cause of the injury;
3. whether the injury arose from the investigational product/protocol;
4. whether the investigator/hospital was negligent;
5. whether the negligence was ordinary negligence, gross negligence or wilful misconduct;
6. applicable statutory clinical-trial compensation rules; and
7. insurance arrangements.

2. Sponsor Indemnification vs. Clinical-Trial Compensation

These concepts should not be confused.

A. Sponsor indemnification

This is primarily a contractual relationship between:

Sponsor ↔ Investigator/Institution

It determines who ultimately bears specified liabilities and litigation expenses.

B. Statutory compensation

This concerns the trial participant's right to compensation for trial-related injury or death.

Under India's New Drugs and Clinical Trials Rules, 2019 (NDCTR), information supplied to a participant must address financial compensation and medical management. In case of trial-related injury, free medical management must be provided for the required period, and in the event of trial-related injury or death, financial compensation is payable in accordance with the Rules.

The CDSCO framework specifically regulates serious adverse events and compensation in clinical trials.

Thus:

Participant → may claim statutory compensation

while

Institution/Investigator → may invoke contractual indemnity against Sponsor, depending on the CTA.

3. Why Medical Malpractice Is Usually an Exclusion

Suppose a sponsor conducts a clinical trial at Hospital X.

A participant receives the investigational drug and suffers an injury.

There are two very different possibilities:

Situation 1 — Injury caused by the investigational product

For example:

• the investigational drug produces an unexpected adverse reaction;
• the participant suffers an injury despite proper administration;
• the protocol itself creates the relevant risk.

This is generally the type of risk for which sponsor indemnification/clinical-trial insurance is intended.

Situation 2 — Injury caused by investigator negligence

For example:

• investigator administers the wrong dose;
• investigator ignores the protocol;
• investigator fails to monitor a participant;
• unqualified personnel perform a procedure;
• hospital fails to provide reasonable medical care.

Here, the sponsor will generally argue:

“This is medical malpractice by the investigator/institution, not a risk arising from the Sponsor's product or protocol.”

Consequently, many CTAs contain an exclusion such as:

“The Sponsor shall not be liable to the extent the claim arises from the negligence, gross negligence, wilful misconduct or breach of the protocol by the Investigator/Institution.”

This allocation is commercially and legally significant.

4. Important distinction: adverse event ≠ medical negligence

This is one of the most important examination points.

An adverse event does not automatically establish negligence.

For example:

A participant takes a new drug exactly according to the protocol and develops a known or unforeseen adverse reaction.

That fact alone does not necessarily establish malpractice.

Conversely, if the investigator administers the drug incorrectly or fails to follow required medical standards, the matter may involve negligence.

Therefore:

Adverse event → medical causation question

Malpractice → breach of applicable standard of care + causation + damage

5. Indian statutory framework

The present framework is principally governed by the New Drugs and Clinical Trials Rules, 2019.

The Rules require information concerning:

• medical management of trial-related injury;
• financial compensation;
• rights of trial participants;
• contact information in case of injury; and
• responsibilities of participants.

The CDSCO continues to maintain the NDCTR regulatory framework and related clinical-trial/ethics-committee requirements.

Earlier, Rule 122-DAB of the Drugs and Cosmetics Rules, 1945 provided a specific framework for serious adverse events, injury/death and compensation. The Government's materials explain that the sponsor had responsibility for financial compensation in appropriate trial-related injury/death cases.

6. Landmark Supreme Court case: Swasthya Adhikar Manch v. Union of India

This is perhaps the most important Indian case concerning clinical-trial regulation and participant protection.

Case

Swasthya Adhikar Manch, Indore v. Union of India

Supreme Court of India, W.P. (C) No. 33 of 2012 and connected matters.

The litigation concerned serious concerns regarding clinical trials, including deaths, serious adverse events, informed consent and regulatory safeguards.

The Supreme Court required the Government to strengthen supervision and scrutinise clinical trials, including consideration of:

1. risk versus benefit;
2. innovation compared with existing therapeutic options; and
3. unmet medical need.

The Court's orders ultimately contributed to significant strengthening of India's clinical-trial regulatory system.

The Government subsequently implemented mechanisms concerning supervision and compensation of clinical-trial participants.

Relevance to indemnification

The case demonstrates an important principle:

Clinical-trial participation is not merely a private contractual arrangement between sponsor and investigator; participant protection is subject to statutory and constitutional regulatory oversight.

Therefore, a sponsor cannot simply rely upon a private indemnity clause to avoid statutory compensation obligations.

7. Indian Medical Association v. V.P. Shantha

Case

Indian Medical Association v. V.P. Shantha,
(1995) 6 SCC 651.

The Supreme Court held that medical services rendered for consideration fall within the concept of "service" under the Consumer Protection Act framework, subject to the qualifications recognized by the Court. Medical practitioners are therefore not immune from liability for deficient medical service merely because they are professionals.

Importance

This case established the foundation for consumer-law claims concerning medical negligence.

Therefore, if an investigator/hospital commits negligent medical treatment, the patient may potentially pursue the appropriate legal remedy against the responsible healthcare provider.

A sponsor's indemnification clause does not necessarily transfer the underlying professional liability away from the negligent doctor.

It may instead determine who bears the financial consequences between contracting parties.

8. Jacob Mathew v. State of Punjab

Case

Jacob Mathew v. State of Punjab,
(2005) 6 SCC 1.

This is the leading Supreme Court authority concerning criminal medical negligence.

The Court distinguished ordinary negligence from the much higher threshold required for criminal liability. Criminal negligence requires a sufficiently serious/gross degree of negligence rather than merely an error of judgment or an unfortunate treatment outcome.

Importance for sponsor indemnification

Suppose a trial participant dies.

The mere fact of death does not automatically establish criminal malpractice by the investigator.

The questions become:

• Was there a breach of professional duty?
• Was the breach sufficiently serious?
• Was there causation?
• Is there expert medical evidence?
• Does the conduct meet the applicable threshold for criminal liability?

This distinction is crucial because contractual indemnification and criminal liability operate differently.

A sponsor cannot contractually indemnify someone against criminal punishment.

An indemnity can generally concern financial liability, defence costs and specified civil/third-party claims, but it does not erase criminal responsibility.

9. Spring Meadows Hospital v. Harjol Ahluwalia

Case

M/s Spring Meadows Hospital & Anr. v. Harjol Ahluwalia,
(1998) 4 SCC 39.

The Supreme Court considered hospital liability arising from negligent treatment. The case involved a child who suffered severe injury after an unqualified nurse administered an excessive dose of medication.

The Court recognized liability and compensation in the consumer-protection context.

Relevance

This case is particularly useful for explaining institutional/hospital responsibility.

A hospital cannot necessarily escape responsibility merely by saying:

“The individual nurse/doctor committed the error.”

For a clinical trial, this becomes significant because the CTA may allocate responsibilities between:

• sponsor;
• principal investigator;
• hospital/institution;
• CRO;
• treating personnel.

The contractual allocation of risk does not necessarily eliminate the patient's underlying legal rights.

10. Savita Garg v. Director, National Heart Institute

Case

Savita Garg v. Director, National Heart Institute,
(2004) 8 SCC 56.

The Supreme Court dealt with medical negligence and the evidentiary responsibilities of hospitals.

Principle

The case is important because hospitals/institutions cannot always simply place the entire evidentiary burden on the patient while withholding relevant records or information.

Clinical-trial relevance

Clinical trials generate extensive documentation:

• consent forms;
• protocol;
• source documents;
• medical records;
• drug-administration records;
• adverse-event reports;
• monitoring reports;
• investigator records.

These documents can become critically important when determining whether an injury resulted from:

(a) the investigational product,

(b) the protocol,

(c) medical negligence,

or

(d) an unrelated medical condition.

11. How a Sponsor Indemnity Clause should be interpreted

Imagine the following clause:

“Sponsor shall indemnify the Institution against all claims arising from injury to a trial participant resulting from the use of the investigational product.”

Suppose the investigator administers 10 times the prescribed dose.

The institution demands indemnification.

The sponsor may argue:

The injury resulted from investigator negligence, not from proper use of the investigational product.

The court would need to examine the actual contractual language and factual causation.

12. Three common indemnity models

Model 1 — Broad sponsor indemnity

Sponsor indemnifies for:

• product-related injury;
• protocol-related injury;
• trial procedures;
• third-party claims;
• defence costs.

But excludes:

• negligence;
• gross negligence;
• wilful misconduct;
• protocol violations by institution.

This is probably the most commercially balanced approach.

Model 2 — Sponsor indemnifies almost everything

The Sponsor agrees to indemnify the Institution except for:

• wilful misconduct;
• gross negligence;
• deliberate violation of law.

This gives the institution substantially greater protection.

Model 3 — Mutual indemnification

Both sides indemnify the other for different categories.

For example:

Sponsor indemnifies Institution for:

• investigational product defects;
• protocol design;
• sponsor breach;
• sponsor negligence;
• sponsor's regulatory violations.

Institution indemnifies Sponsor for:

• investigator negligence;
• hospital negligence;
• protocol deviation;
• breach of law;
• wilful misconduct.

This is often the clearest risk-allocation structure.

13. Example

Assume:

Sponsor: ABC Pharma
Investigator: Dr. X
Institution: City Hospital
Participant: P

The protocol requires Drug A to be administered at 50 mg.

Dr. X accidentally administers 500 mg.

P develops severe kidney injury.

Participant's position

P may pursue the legally available remedies for trial-related injury.

Sponsor's position

The sponsor may have statutory obligations concerning trial-related compensation depending upon the facts and regulatory determination.

Institution's position

The hospital may face liability for negligence by its personnel.

Contractual position

If the CTA says:

“Sponsor shall not indemnify claims arising from negligence of Investigator or Institution,”

the sponsor may have a contractual defence to the hospital's indemnity claim.

Thus:

Participant compensation ≠ Sponsor's contractual indemnity ≠ Investigator's malpractice liability.

That distinction is fundamental.

14. What happens when both the drug and negligence contribute?

This is much more complicated.

Suppose:

• Drug A has a known renal risk; and
• the investigator also fails to monitor renal function.

The injury may have multiple causes.

The court/regulator may have to determine:

1. Was the injury trial-related?

2. Was there negligence?

3. What proportion of causation is attributable to each factor?

4. What does the CTA say about indemnification?

5. What does the insurance policy cover?

This is why good CTAs contain detailed provisions concerning causation, exclusions, claims handling and insurance.

15. Does indemnity protect a negligent doctor?

Generally, not absolutely.

An indemnity clause is not a licence to practise negligently.

For example:

“Sponsor will indemnify Investigator against all claims.”

does not necessarily mean that the sponsor will bear every conceivable consequence of the investigator's negligence.

Courts generally examine the actual language and construction of the contract, together with applicable statutory rules.

A recent Supreme Court decision, VPS Healthcare Pvt. Ltd. v. Prabhat Kumar Srivastava (2026), illustrates the importance of examining the precise wording and legal character of an indemnity obligation under Sections 124–125 of the Indian Contract Act.

16. Sections 124 and 125 — Indian Contract Act

The basic statutory framework for contractual indemnity comes from the Indian Contract Act, 1872.

Section 124

A contract of indemnity is a contract by which one party promises to save the other from loss caused by the conduct of the promisor or another person.

Section 125

The indemnity-holder may, subject to the statutory conditions, recover certain losses/costs incurred in relation to the matter covered by the indemnity.

Therefore, when analysing a Sponsor Indemnity clause, the first question is:

What exactly has the Sponsor promised to indemnify?

The second question is:

What loss or liability falls within that promise?

17. Indemnification and insurance are different

Another important distinction:

Indemnity

A contractual promise to bear specified losses/liabilities.

Insurance

A risk-transfer mechanism under an insurance contract.

A CTA may require the sponsor to maintain:

• clinical-trial insurance;
• product liability insurance;
• professional indemnity insurance;
• general liability coverage.

The existence of insurance does not automatically determine whether the sponsor is contractually liable.

Similarly, an indemnity clause does not necessarily mean that every claim will be covered by insurance.

18. Key cases to remember for examinations

The clinical-trial-specific jurisprudence is less extensive than the general medical-negligence jurisprudence, so Swasthya Adhikar Manch and the statutory NDCTR framework should be used together with the general negligence cases.

19. Exam-ready legal proposition

A good answer can be framed as follows:

Sponsor indemnification in a clinical trial is a contractual allocation of risk between the sponsor and the investigator/institution. It does not, by itself, extinguish the statutory rights of a trial participant or immunize a medical professional from liability for negligence. Under the New Drugs and Clinical Trials Rules, 2019, trial-related injury/death can attract medical management and financial compensation obligations. Whether the sponsor must indemnify an investigator or institution for a particular malpractice claim depends primarily upon the wording of the Clinical Trial Agreement, the causal connection between the trial and the injury, and any contractual exclusions for negligence, gross negligence, wilful misconduct or protocol violations. The principles in Swasthya Adhikar Manch v. Union of India, Indian Medical Association v. V.P. Shantha, Jacob Mathew v. State of Punjab, Spring Meadows Hospital v. Harjol Ahluwalia and Savita Garg v. National Heart Institute help distinguish statutory participant compensation, medical negligence, institutional liability and contractual indemnification.

Bottom line

Sponsor indemnification does not mean “Sponsor is liable for every medical mistake.” It means the sponsor has agreed to assume specified categories of financial/legal risk. The decisive issues are the CTA wording, statutory clinical-trial obligations, causation, negligence, protocol compliance, and applicable insurance.

For the primary regulatory text, see the CDSCO's New Drugs and Clinical Trials Rules, 2019 materials.

This is an educational overview of Indian law, not case-specific legal advice. For an actual CTA or indemnity dispute, the exact indemnity, exclusion, insurance and governing-law clauses should be reviewed together